Podcasts about icecap

Tired of boring, lookalike crossovers? The 2025 Alfa Romeo Tonale Veloce is the answer to that issue. It and the all-new 2026 Toyota Corolla FX are our road test vehicles this week. Host Jack Nerad found himself at the controls of the Tonale, a compact SUV that brings Italian luxury and performance to a pretty ho-hum segment. With its sharp design, 268-horsepower turbo engine, adaptive suspension, and upscale interior, it offers a distinctive alternative in a crowded class. The Veloce trim that Jack Nerad tested features adaptive dampers, optional 20-inch alloy wheels, and performance-tuned steering for sharper handling. Its turbocharged four-cylinder engine is teamed with standard with all-wheel drive and a nine-speed automatic transmission. Inside, the Tonale offers leather-trimmed heated and ventilated front seats, a 10.25-inch Uconnect 5 touchscreen with wireless Apple CarPlay and Android Auto, and a 12.3-inch digital gauge cluster. With its distinctive styling, including the test car's optional Verde Fangio green paint and signature LED lighting, the Tonale Veloce brings premium European character to the compact SUV segment. At a special Toyota event in Plano, Texas, guest co-host Matt DeLorenzo took the wheel of the all-new 2026 Toyota Corolla Hatchback FX Edition. The colorful trim builds on the SE model with unique visual and functional upgrades that nod to the original 1980s-vintage FX16. It features a black vented sport wing for added aerodynamic flair, 18-inch gloss white alloy wheels, and retro FX badging on the rear hatch. Inside, it offers suede-trimmed sport seats accented by orange contrast stitching, a seven-inch digital gauge cluster, and standard wireless charging. The FX is powered by a 2.0-liter four-cylinder engine producing 169 horsepower, and offers a sporty suspension setup and a manufacturer-estimated 33 mpg combined. Only 1,600 units will be offered in the U.S., and it will come in three vibrant color choices: Inferno, Ice Cap, and Blue Crush Metallic. In our news segment, we will discuss Cadillac's debut of the 2026 Optiq-V, a performance-oriented electric SUV boasting 519 horsepower, an estimated 275-mile range, and Cadillac's first use of the North American Charging Standard. With dramatic styling, launch control, and a 33-inch LED display, it's yet another move in General Motors' EV strategy. That strategy might take its lumps as the Trump Administration takes steps to roll back Biden-era fuel economy regulations, citing legal issues with the way EVs were factored into earlier targets. While immediate changes are limited, this signals a broader shift in auto policy that could ease pressure on automakers but potentially slow progress toward emissions reduction. Speculation swirled this week about Porsche manufacturing cars in the U.S., but the company denied any such plans, citing low volumes and high costs. Despite that, ongoing tariff talks and Volkswagen Group's broader American investment strategy suggest the door may not be fully closed. Matt DeLorenzo and Jack Nerad will share their thoughts on those prospects. Tesla also made headlines with the resignation of Milan Kovac, head of its Optimus robot project. Kovac played a major role in developing Tesla's humanoid robotics program, and his departure raises questions about the future of the bold, still-developing initiative. In Los Angeles, the Petersen Automotive Museum has launched its *“Totally Awesome! Cars and Culture of the '80s and '90s”* exhibit. With standout vehicles like the McLaren F1, Audi S1 E2 rally car, and Ferris Bueller's Ferrari replica, the show is a nostalgic and immersive look at two transformative automotive decades. Our special guest this week is Doron Levin, a longtime automotive journalist and editor at BetterInvesting, who joins us to share his insights on where the industry is heading. Jack caught up with him at a Toyota event in Texas. Finally,

A team of Canadian and Danish scientists are drilling deep into the Müller Ice Cap on Axel Heiberg Island in the Canadian Arctic to extract an ice core containing up to 20,000 years of climate history. This ambitious project, led by glaciologist Dorthe Dahl-Jensen and supported by a $10-million Canadian research chair, aims to uncover data about past climate conditions, including volcanic eruptions and ocean activity, which can help predict future environmental changes. Guest: Dr. Dorthe Dahl-Jensen - Canada Excellence Research Chair in Arctic Ice, Freshwater-Marine Coupling and Climate Change in the Centre for Earth Observation Science at the University of Manitoba Learn more about your ad choices. Visit megaphone.fm/adchoices

In this hour of Cashing Out, Greg Peterson previews Sunday's college basketball games. Plus, Jonathan Davis, VSiN NHL Betting Analyst & Host of "Ice Cap" on SiriusXM joins the show to preview Sunday's NHL action.See omnystudio.com/listener for privacy information.

In this hour of A Numbers Game hosts Gill Alexander and Kelley Bydlon are joined by Paul Carr, TruMedia Sports & Expected Value Podcast, as they preview today's slate in the Champions League. Also on the show is Jonathan Davis, VSiN NHL Betting Analyst & Host of Ice Cap on Sirius XM NHL, as they give a betting preview of today's NHL slate.See omnystudio.com/listener for privacy information.

In this hour of A Numbers Game hosts Gill Alexander and Kelley Bydlon are joined by Paul Carr, TruMedia Sports & Expected Value Podcast, as they preview today's slate in the Champions League. Also on the show is Jonathan Davis, VSiN NHL Betting Analyst & Host of Ice Cap on Sirius XM NHL, as they give a betting preview of today's NHL slate.See omnystudio.com/listener for privacy information.

In this hour of Money Moves hosts Stormy Buonantony and Geoff Schwartz are joined by Jonathan Davis, VSiN NHL Betting Analyst & Host of Ice Cap on SiriusXM NHL, as they give a betting preview of today's NHL slate. Also in the show, the hosts dive into the prop market for the Super Bowl 59 matchup between the Chiefs & Eagles.See omnystudio.com/listener for privacy information.

It's time for another listing party, as we tackle perhaps the most controversial Sonic soundtrack(s) ever composed. Special guest RecD chimes in as we look back at Sonic 3 & Knuckles, a soundtrack that is perhaps known less for the music it features and more for the many mysteries behind its creation. Which are better, the original tracks, or the "original" tracks? Whether you're a dedicated fan or just a stranger in Moscow, listening to the gang's thoughts just might be the happiest days of your life. (0:00:00) Intro/Main topic: Sonic 3 & Knuckles listening party (0:17:45) Title track (0:20:52) Menu themes (0:27:07) Jingles (0:40:25) Bonus/special stages (0:51:26) Knuckles theme (0:56:41) Boss themes (1:02:02) Multiplayer stages (1:08:00) Angel Island (1:12:52) Hydro City (1:16:10) Marble Garden (1:20:17) Carnival Night (1:30:58) Ice Cap (1:41:38) Launch Base (1:53:58) Big Arms (1:56:21) Mushroom Hill (1:59:30) Flying Battery (2:02:35) Sandopolis (2:05:46) Lava Reef (2:09:36) Sky Sanctuary (2:13:41) Death Egg (2:16:34) Doomsday (2:18:55) Credits themes (2:26:17) Other tracks (2:30:00) Final thoughts (2:37:46) Outro Amie Waters on Linktree RecD on YouTube What we know about the Sonic 3 soundtrack

In this hour of Money Moves hosts Stormy Buonantony and Matt Brown are joined by Jonathan Davis, Host of Ice Cap on SiriusXM, Show Me The Money Hockey Betting Podcast, as they give a betting preview of the upcoming season for the NHL. Also in the show, it is time for another edition of "Why Not Wednesday".See omnystudio.com/listener for privacy information.

In the final hour of Sharp Money hosts Dave Ross and Jared Smith are joined by Jonathan Davis, Host of "Ice Cap" on SiriusXM, "Show Me The Money" Podcast, as they break down the NHL free agency period and discuss who the winners and losers were. Also in the show, the hosts continue with a betting preview of the AFC East.See omnystudio.com/listener for privacy information.

In the final hour of Sharp Money hosts Dave Ross and Jared Smith are joined by Jonathan Davis, Host of "Ice Cap" on SiriusXM, "Show Me The Money" Podcast, as they break down the NHL free agency period and discuss who the winners and losers were. Also in the show, the hosts continue with a betting preview of the AFC East.See omnystudio.com/listener for privacy information.

GUEST 1 OVERVIEW: Salvatore “Sal” Greco is a Former 14 year New York Police Department (NYPD) veteran, and a Sicilian-American. Being a strict fitness enthusiast, food connoisseur, and cigar aficionado Sal is no stranger to the Good and Evil in our lives. His origin story began with food industry work and a love for how it brought everyone together. GUEST 2 OVERVIEW: Mark Anderson is the host of the "Stop The Presses" on Republic Broadcasting Network and founder of thetruthhound.com - He's an independent journalist who focuses on freedom, current events and globalist initiatives such as smart cities and sustainable development. GUEST 3 OVERVIEW: Joe Bastardi is a weather forecaster and climate change skeptic. He worked for AccuWeather from 1978 until 2011 when he joined WeatherBELL Analytics LLC where he now works as Chief Forecaster with Joseph D'Aleo, the climate change skeptic who founded Icecap.us

In the second hour of VSiN Tonight, hosts Dave Ross and Will Hill are joined by, the host of Ice Cap on SiriusXM Jonathan Davis to preview the Stanley Cup Finals. Plus a look at the odds for who will be the starting QB for the teams with QB's battling for the starting job. See omnystudio.com/listener for privacy information.

In hour two of A Numbers Game hosts Gill Alexander and Kelley Bydlon are joined by Jonathan Davis, Host of Ice Cap on SiriusXM NHL, as they talk about the Stanley Cup Playoffs. Jason Weingarten also joins the show as they talk about the MLB and French Open.See omnystudio.com/listener for privacy information.

In hour two of A Numbers Game hosts Gill Alexander and Kelley Bydlon are joined by Jonathan Davis, Host of Ice Cap on SiriusXM NHL, as they talk about the Stanley Cup Playoffs. Jason Weingarten also joins the show as they talk about the MLB and French Open.See omnystudio.com/listener for privacy information.

GUEST 1 OVERVIEW: Corinne Cliford is a highly accomplished and versatile independent journalist based in Washington DC. She has pioneered the field of video journalism known as Active IRT (In Real Time), focusing on capturing real events as they unfold live and without any editing. X: @corinnecliford GUEST 2 OVERVIEW: Joe Bastardi is a weather forecaster and climate change skeptic. He worked for AccuWeather from 1978 until 2011 when he joined WeatherBELL Analytics LLC where he now works as Chief Forecaster with Joseph D'Aleo, the climate change skeptic who founded Icecap.us GUEST 3 OVERVIEW: Art Del Cueto is the National Border Patrol Council VP. 

In hour one of VSiN PrimeTime, Dave Ross and Holden Kushner recap the Mavericks and Timberwolves game from Sunday night. They also give their thoughts on how impressive the Mavericks have been in the series. Jonathan Davis, Host of Ice Cap on Sirius XM joins the show to talk NHL Playoffs. The guys take a look at the NL East and discuss the impact of the Braves losing Ronald Acuna Jr for the season. See omnystudio.com/listener for privacy information.

In hour three of VSiN PrimeTime, Tim Murray and Jonathan Von Tobel are joined by Jonathan Davis, Host of Ice Cap on Sirius XM to break down the NHL Playoffs Conference Matchups. The guys also take a look at the top quarterbacks who have hit the transfer portal and evaluate their odds to win the Heisman. See omnystudio.com/listener for privacy information.

In hour two of "Sunday Bet Prep" hosts Dave Ross and Will Hill, are joined by Jonathan Davis the host of "Ice Cap" on SiriusXM to discuss the NHL playoffs. Plus a look into potential division winners in the NFL. A recap of the Dallas Mavericks series win over the OKC Thunder.See omnystudio.com/listener for privacy information.

GUEST 1 OVERVIEW: Rebecca Walser is the Founder and CEO of Walser Wealth Management. She received her undergraduate degree in Finance from the University of South Florida, summa cum laude, her law degree from The University of Florida, magna cum laude, and her advanced law degree in taxation from NYU. Rebecca is a Wealth Strategist, Tax Attorney, and has her Global MBA from The London School of Economics.    GUEST 2 OVERVIEW: Joe Bastardi is a weather forecaster and climate change skeptic. He worked for AccuWeather from 1978 until 2011 when he joined WeatherBELL Analytics LLC where he now works as Chief Forecaster with Joseph D'Aleo, the climate change skeptic who founded Icecap.us    

In hour three of VSiN PrimeTime, Tim Murray and Jonathan Von Tobel are joined by Jonathan Davis, Host of Ice Cap on Sirius XM Radio as he previews the 2nd round of the NHL Playoffs. The guys also continue their breakdown of game 2 of the Nuggets and Timberwolves. See omnystudio.com/listener for privacy information.

In hour two of Follow the Money, Mitch Moss and Pauly Howard are joined by Jonathan Davis, Host of "Ice Cap" on SiriusXM, as they talk about the Stanley Cup Playoffs and tonight's slate. Also on the show, the hosts give out their plays in "In Pocket Plays".See omnystudio.com/listener for privacy information.

In hour two of Follow the Money, Mitch Moss and Pauly Howard are joined by Jonathan Davis, Host of "Ice Cap" on SiriusXM, as they talk about the Stanley Cup Playoffs and tonight's slate. Also on the show, the hosts give out their plays in "In Pocket Plays".See omnystudio.com/listener for privacy information.

Hosts Mike Palm & Adam Kaufman invite Jonathan Davis, host of "Ice Cap" to discuss MLB, NHL, and The Masters. See omnystudio.com/listener for privacy information.

In the second hour of VSiN Primetime, hosts Tim Murray & Jonathan Von Tobel are joined by Reed Kuhn, Author of Fightnomics to discuss his best bets for this weekend's UFC Fight Night highlighted by Allen vs Curtis 2 and preview next weekend's UFC 300. Jonathan Davis of The Ice Cap on SiriusXM joins the show to share his plays for tonight's NHL slate. They also look at consensus picks with major betting sides on those picks for the 2024 NFL Draft. See omnystudio.com/listener for privacy information.

On today's show, Mark Powell discusses the squatter crisis hitting Atlanta as property owners see homes morph into drug and prostitution dens. Later, Dr. Kelly Victory discusses President Biden's health and the continued push on dangerous vaccines. Also, Joe Bastardi discusses global warming and the latest in climate. GUEST 1 OVERVIEW: Mark Powell is a Real Estate Broker and Owner of Discovery Property Group. He is also the 2024 President-Elect for the San Diego Association of Realtors. GUEST 2 OVERVIEW: Dr. Kelly Victory MD is a board-certified trauma and emergency specialist with over 30 years of clinical experience. She served as CMO for Whole Health Management, delivering on-site healthcare services for Fortune 500 companies. She holds a BS from Duke University and her MD from the University of North Carolina. GUEST 3 OVERVIEW: Joe Bastardi is a weather forecaster and climate change skeptic. He worked for AccuWeather from 1978 until 2011 when he joined WeatherBELL Analytics LLC where he now works as Chief Forecaster alongside Joseph D'Aleo, the climate change skeptic who founded Icecap.us.

Happy anniversary to us! To celebrate 50 episodes of The Hill Is Always Greener, we're taking a look back at a game currently celebrating its own milestone anniversary, Sonic the Hedgehog 3! The capstone to the original trilogy provides for endless discussion, including how a whole separate game was made because of McDonald's, the *multiple* renditions of many music tracks, and the ongoing debate as to just what color Knuckles actually is. In fact, this episode ended up being so huge that, much like Sonic 3 itself, we had to split it in two! Tune in next week for our second half, all about Sonic & Knuckles! (0:00:00) Intro/Main topic: Sonic the Hedgehog 3 (& Knuckles) (0:08:45) The box art (0:11:38) The split/"lock-on technology" (0:21:58) Competition mode (0:24:55) Knock knock, it's Knuckles (0:28:20) Other changes and new features (0:36:32) The story (0:40:19) Our various versions (0:46:47) Angel Island (and Blue Spheres) (1:04:25) Hydro City (1:11:36) Marble Garden (1:17:32) Carnival Night (1:23:30) Ice Cap (1:30:03) Launch Base Amie Waters on Linktree The Sonic 3 and Laputa Connection Retronauts Episode 524: Sonic 3 & Knuckles, Part 1 Retronauts Episode 542: Sonic 3 & Knuckles, Part 2

On today's show, Joe Bastardi discusses Global Warming and the Latest in Climate. GUEST 1 OVERVIEW: Timothy is a political pundit and grassroots activist with a long history in GOP and Conservative politics. He has served in elected local government positions in Massachusetts and is a serial entrepreneur and business consultant. Timothy is also the co-Founder of MAGA Institute and the co-host of the MAGA Institute Podcast. He hosts "The Reckoning with Timothy Shea" on TNT. Find out more here: https://tntradio.live/presenters/timothy-shea/ GUEST 2 OVERVIEW: Eric Swanson is a Retired Special Operations Supervisor. GUEST 3 OVERVIEW: Joe Bastardi is a weather forecaster and climate change skeptic. He worked for AccuWeather from 1978 until 2011 when he joined WeatherBELL Analytics LLC where he now works as Chief Forecaster with Joseph D'Aleo, the climate change skeptic who founded Icecap.us

On today's show, Joe Bastardi discusses Global Warming and the Latest in Climate. GUEST OVERVIEW: Joe Bastardi is a weather forecaster and climate change skeptic. He worked for AccuWeather from 1978 until 2011 when he joined WeatherBELL Analytics LLC, where he now works as Chief Forecaster alongside Joseph D'Aleo, the climate change skeptic who founded Icecap.us.

Doggone Controversy, Tackle Ban Sacked, Ice Cap in Peril, OJ minus AI & Hoops for Travelers!

Episode Notes Welcome, Junior Wizards! This week, Jeff and Aaron discover a new area within Moon Crescent called The Ice Cap Mountains. The best place to get a cup of hot cocoa? Yes, and nothing more. This podcast is powered by Pinecast.

Pre-conference PDX Audio Clips This Cider Chat Live features clips from CiderCon 2024 which took place in Portland, Oregon. What was particularly unique about this year was the ice storm that took place. Pictured below is a car driven from the border of Oregon and California to PDX. It is incased in ice and is a testament of just how ferocious the storm was. Despite the ice, the cider kept pouring. Enjoy this Cider Chat Live Ander's car and its Ice Cap when he arrived at the main hotel  

The radio version of Space Patrol aired from October 4, 1952 to March 19, 1955, for a total of 129 episodes. The same cast performed on both the radio and television versions. The writers, scripts, and directors were also the same for both versions. However, the radio broadcasts were not limited by studio sets and could therefore be more expensive in scope than the television programs. This allowed for more elaborate special effects and sound design, which helped to create a more immersive experience for listeners. While there was seldom any deliberate crossover between the two versions, some of the television villains regularly appeared on the radio (notably Prince Bacarratti). Additionally, both the TV and radio versions explored the rogue planet's invasion of the Space Patrol universe during the "Planet X" story. This was a major story arc that spanned multiple episodes and helped to raise the stakes for the characters. While the radio series lacked the sophistication of sci-fi shows like the later X Minus One, it was enjoyed by many as a throwback to the Golden Age of space opera popularized in the 1930s by pioneering magazine editor Hugo Gernsback. Of the original broadcasts, only 117 survive. 97 are on the OTR site and a few others on torrent sites. --- Support this podcast: https://podcasters.spotify.com/pod/show/dwight-allen0/support

Today we're heading down to the white continent of Antarctica. This vast land holds an extremely special place in my heart and this was my second trip to the continent. This time I visited by flying over from South Africa and staying at one of White Desert's beautiful camps called Echo Camp.  I took along my recording equipment and am so glad I did because I think you'll find the stories that follow quite inspirational. While my day to day was focused on mountaineering activities, what was most special about the trip was meeting the team and learning about the incredible amount of logistics that go into the camp and transporting scientists and dignitaries to and from Antarctica.  There's something about being secluded with humans from around the world, in place that waves no flag. My guests today - Neil, Stuart, James, Sean, and Dumi share how months on end in Antarctica have inspired and changed them and tell stories of some incredible things they've experienced  I hope you enjoy this special episode of Luxury Travel Insider.   Learn more at www.luxtravelinsider.com   Connect with me on Social: Instagram LinkedIn  

It's just Josh and the booth team at the Roach Motel this week. And we've got a lot of stories about F-A-M-I-L-Y on a kissing cousins episode of The Josh Potter Show.     PLUS!   Worse than Animals   Meteorite Ribs   Brotherly Love   Headless in Love Hotel   Shovel Head   Looking a Li'l Lezz-y    Brotherly Manatee Love     This week's music is “Ice Cap” by Griff Parker     *** See Josh Live!   Sept 3, The Nitecap (The Post-It Show), Burbank, CA   Sept 23, The Siren Theater, Portland OR   Sept 29 - Oct 1, Skankfest, Las Vegas, NV   October 20 & 21, SoulJoel's, Pottstown, PA    October 26, Cobb's Comedy Club, San Francisco, CA   October 29, The Here-After, Seattle, WA    December 1, 2, & 3, La Jolla Comedy Store, La Jolla, CA   December 22 & 23, Side Splitters Comedy Club, Tampa, LA   https://linktr.ee/Josh_Potter   *** Check out the Patreon:   https://www.patreon.com/TheJoshPotterShow   Josh Potter's New Channel:   https://www.youtube.com/channel/UCpREVmHBIx4QIQLA5ZUx0wA Josh Potter's New Email:   joshpottershow@gmail.com   Josh Potter Links   https://www.cameo.com/josh_potter   Twitch Streams are back! https://twitch.tv/josh_potter   https://twitter.com/j_potter   https://instagram.com/josh_potter     ***SPONSORS*** Get 50% off up to $10 on your next DoorDash order of $15 or more when you sign up for the DashPass Student plan and use code JOSHPOTTERBTC

In hour two of Live Bet Saturday, hosts Jonathan Von Tobel and Mike Somich are joined by Jonathan Davis, Host of Ice Cap on SiriusXM NHL, as they preview the upcoming Stanley Cup Playoffs card. Also on the show is Mikhail Miranda, VSiN F1 Technical Analyst, as they discuss the Monaca Grand Prix odds.See omnystudio.com/listener for privacy information.

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss the CLEAR study in renal cell carcinoma, a new exploratory analysis combining the TheraP and VISION trials in metastatic urothelial cancer, and compelling advances in prostate cancer and across GU oncology in advance of the 2023 ASCO Annual Meeting.  TRANSCRIPT Dr. Neeraj Agarwal: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Neeraj Agarwal, your guest host for the ASCO Daily News Podcast today. I'm the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah Huntsman Cancer Institute, and editor-in-chief of the ASCO Daily News. I'm delighted to welcome Dr. Jeanny Aragon-Ching, a GU medical oncologist and the clinical director of the Genitourinary Cancers Program at the Inova Schar Cancer Institute in Virginia.   Today, we'll be discussing some key abstracts in GU oncology that will be featured at the 2023 ASCO Annual Meeting.  Our full disclosures are available in the show notes and disclosures of all guests on the podcast can be found on our transcript at asco.orgDNpod.   Jeanny, it's great to have you on the podcast today. Dr. Jeanny Aragon-Ching: Thank you so much, Dr. Agarwal, for having me. Dr. Neeraj Agarwal: Jeanny, let's begin with Abstract 4502 regarding long-term updated results on the CLEAR study. The abstract reports the final, prespecified overall survival analysis of the CLEAR trial, a four-year follow-up of lenvatinib plus pembrolizumab versus sunitinib in patients with advanced renal cell carcinoma. Dr. Jeanny Aragon-Ching: Yes, I would be happy to. So, just as a reminder, the combination of lenvatinib and pembrolizumab was initially approved by the FDA in August 2021 for first-line treatment of adult patients with advanced renal cell carcinoma. So, this was based on significant benefits that were seen in progression-free survival, which was a primary endpoint, but also showed improvement in the overall response rates compared with sunitinib in first-line advanced renal cell carcinoma.   So this abstract reports on longer-term follow-up now at a median of 49.8 months, and PFS favored the combination lenvatinib and pembrolizumab compared to sunitinib across all MSKCC risk groups, and PFS benefit versus lenvatinib and pembro compared to sunitinib was maintained with a hazard ratio of 0.47. And even overall survival was also maintained with the combination with a hazard ratio of 0.79, and the overall survival favored the combination across all risk groups. If we look at the CR rate, it was 18.3% for the combination compared to 4.8% with sunitinib, unless patients in the combination arm received subsequent anticancer therapies, and that's intuitive. And the PFS2 was also longer with the combination at 43 months compared to 26 months. Now, it is important to note that grade III or more treatment-related adverse events did occur in about 74% of the patients in the combination of lenvatinib and pembro, compared to 60.3% in patients with sunitinib. Dr. Neeraj Agarwal: Jeanny, this is good news. So the main message from the abstract is that sustained results from this combination of lenvatinib plus pembrolizumab are being seen even after a longer follow-up of more than four years.  Dr. Jeanny Aragon-Ching: Yes, I agree. So now, moving on, Neeraj, to a different setting in the RCC space, let's look at Abstract 4519, which is titled “Efficacy of First-line Immunotherapy-based Regimens in Patients with Sarcomatoid and/or Rhabdoid Metastatic Non-Clear Cell RCC: Results from the IMDC,” which will be discussed by Dr. Chris Labaki. So, Neeraj, based on this abstract, can you tell us a little bit more about the impact of these adverse pathologic risk features in non-clear cell RCC?  Dr. Neeraj Agarwal: Of course. So, using real-world patient data, the IMDC investigators compared the outcomes of patients with metastatic non-clear cell RCC who were treated with immunotherapy-based combination regimens versus those who were treated with VEGF-TKIs alone. They also assessed the impact of sarcomatoid and rhabdoid features on response to IO-based combinations versus VEGF-TKIs. Of 103 patients with metastatic non-clear cell RCC who had rhabdoid or sarcomatoid features, 32% of patients were treated with immunotherapy-based combinations.   After adjusting for confounding factors, the authors show that those treated with a combination of two immune checkpoint inhibitors or an immune checkpoint inhibitor with a VEGF-TKI combination had significantly improved overall survival, which was not reached in the immunotherapy combination group versus seven months within the VEGF-TKI group. Time to treatment failure and objective responses were also prolonged, significantly higher, and better in the immunotherapy groups compared with patients who were treated with VEGF-TKIs alone. Interestingly, if you look at those 430 patients with metastatic non-clear cell RCC who did not have sarcomatoid or rhabdoid features, they didn't seem to benefit with immunotherapy-based combinations.  Dr. Jeanny Aragon-Ching: This is an exciting update, Neeraj. What are the key takeaways from this abstract? Dr. Neeraj Agarwal: So the main takeaway is if you see a patient with advanced non-clear cell RCC who has sarcomatoid and rhabdoid features, there appears to be a rather substantial and selective benefit with IO-based combinations. And in this context, I would like to highlight the ongoing SWOG 2200 trial also known as PAPMET2 trial, which is comparing the combination of cabozantinib plus atezolizumab. So immuno-therapy-based combinations versus cabozantinib alone in advanced papillary renal cell carcinoma setting. So this trial is being led by Dr. Benjamin Maughan and Dr. Monty Pal. And I like to encourage our listeners to consider referring their patients for involvement in this federally funded trial so that we can validate the data from this retrospective study in a prospective way. So, Jeanny, let's now move on to another important disease type which is urothelial carcinoma. There is a very recent accelerated FDA approval of the drug combination of enfortumab vedotin and pembrolizumab for cisplatin-ineligible metastatic urothelial carcinoma patients. This is Abstract 4505, which is being presented by Dr. Shilpa Gupta and colleagues. Can you please tell us more about this update? Dr. Jeanny Aragon-Ching: Yeah, absolutely. So, as you mentioned, Neeraj, the FDA just granted accelerated approval in April 2023 for this combination of enfortumab vedotin or EV, which is and ADC, antibody drug conjugate against nectin-4 and the PD-1 inhibitor pembroluzimab. So it's a combination for patients with locally advanced or metastatic urothelial carcinoma who are considered cisplatin ineligible. So this is nearly a four-year follow-up.   So as a reminder, this was a phase 1b/2 trial that included 45 patients and it had a primary endpoint of safety and tolerability although the key secondary endpoints included confirmed overall responses, duration of response, progression-free survival, and the resist criteria was investigated via investigator and BICRs which is in a blinded independent central review. Even overall survival was a key secondary endpoint.  So, the bottom line was the confirmed overall response by BICR was 73.3%, the disease control rate was about 84%, and the CR rate was 15.6% with a PFS of close to 13 months, and a 12-month overall survival rate of 83%. However, it is important to cite that there were treatment-related adverse events including skin reactions in 66%, neuropathy occurred in 62%, and ocular disorders in 40%. And there was a little bit of pneumonitis in close to 9%, colitis, and hypothyroidism, so there are side effects to watch out for.  Dr. Neeraj Agarwal: So, Jeanny this is great. What is the key takeaway from this trial?  Dr. Jeanny Aragon-Ching: So I think the most important thing is we now have a new combination of EV and pembro which shows very promising responses and survival in part which led to the FDA accelerated approval in the cisplatin-ineligible population of patients. However, we must note that the phase 3 trial of EV302 will ultimately establish which approach is really beneficial for all of our cisplatin-ineligible patients, either a carboplatin-based chemotherapy regimen or a non-platinum-based regimen such as EV and pembro. Dr. Neeraj Agarwal: Thanks Jeanny, would you like to discuss any other study in the bladder cancer space? Dr. Jeanny Aragon-Ching: Absolutely. I think Abstract 4508 from Dr. Seth Lerner and colleagues will be very relevant to our colleagues. This abstract is SWOG S1011, which is a phase 3 surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at the time of radical cystectomy for muscle-invasive bladder cancer.  Dr. Neeraj Agarwal: Yes. So this trial, as you said, is an important trial which randomized in a one-on-one fashion 618 patients with muscle-invasive bladder cancer undergoing radical cystectomy, and these patients were randomized to either standard lymph node dissection or an extended lymph node dissection. And standard lymph node dissection included, as we know, external and internal iliac and operative lymph node. The extended lymph node dissection included lymph nodes up to aortic bifurcation which included common iliac, presciatic, and presacral lymph nodes. At a median follow-up of approximately 6 years, there was no disease-free survival or overall survival benefit in patients undergoing an extended lymph node dissection compared to standard lymph node dissection. And extended lymph node dissection was also associated with greater morbidity and preoperative mortality. Dr. Jeanny Aragon-Ching: Very interesting data, Neeraj. So these results, I think, will be very useful for a lot of our surgical colleagues in both academia and the community who may still be inclined to perform extended lymphadenectomy during cystectomy. This study shows that it's actually not necessary. Dr. Neeraj Agarwal: Absolutely. So now let's move on to another disease type, which is very important - prostate cancer. There are several practice-informing abstracts that are worthwhile discussing. The first of these involves Abstract 5002, which looks at the impact of the PSA nadir as a prognostic factor after radiation therapy for localized prostate cancer, which will be presented by Dr. Praful Ravi and  colleagues. Jeannie, can you please tell us more about this abstract? Dr. Jeanny Aragon-Ching: Yeah, definitely. So this abstract, as you mentioned, Neeraj, is a prognostic impact of PSA nadir of more than or equal to 0.1 nanogram per ml within six months after completion of radiotherapy for localized prostate cancer - an individual patient data analysis of randomized trials from the ICECaP Collaborative. Basically, it refers to an attempt to evaluate early surrogate measures to predict for long term outcomes such as prostate cancer-specific survival, metastases-free survival, and overall survival. So they looked at a big registry from the ICECaP collaboration that included 10,415 patients across 16 randomized controlled trials. And those men underwent treatment for intermediate risk and high risk prostate cancer treated with either radiation therapy alone in about a quarter of patients, or they got RT with short-term ADT in about 58% of patients, and 17% of them got RT with long-term ADT.  So, after a median follow-up of ten years, what they found was, if you had a PSA nadir that is over or equal to 0.1 nanogram per ml within six months after completion of radiation therapy, it was associated with worse prostate cancer-specific survival, metastases-free survival, and overall survival. For instance, the five-year metastases-free survival for those who achieved a PSA nadir of less than 0.1 was 91% compared to those who did not, which was 79%. Therefore, they concluded that if you achieve a bad PSA of 0.1 or above within six months after you completed radiation, you had worse outcomes.  Dr. Neeraj Agarwal: Jeanny, what is the key takeaway message from this study? Dr. Jeanny Aragon-Ching: The key takeaway from this ICECaP analysis is that this information would be very important to augment a signal-seeking endpoint, especially for clinical trial development, so that we can develop further strategies to de-escalate for those who don't need systemic intensification or therapy intensification versus escalation for those who really do. Dr. Neeraj Agarwal: So, my radiation oncology colleagues need to watch out for those patients who do not achieve a PSA of less than 0.1 nanogram per ml within the first six months of finishing radiation therapy. Very interesting data.  Dr. Jeanny Aragon-Ching: Yes, absolutely. So. Neeraj another important abstract for our fellow clinicians, switching gears a little bit now, is Abstract 5011, which is titled “Do Bone Scans Overstage Disease Compared to PSMA PET?” This was an international, multicenter retrospective study with blinded, independent readers. Can you tell us more about this abstract? Dr. Neeraj Agarwal: Yes, a relatively small retrospective study, but still pertinent to our practice. So I'll summarize it. This study by Dr. Wolfgang Fendler and colleagues evaluated the ability of bone scans to detect osseous metastasis using PSMA PET scan as a reference standard. So in this multicenter retrospective study, 167 patients were included, of which 77 patients were at the initial staging of prostate cancer, 60 had biochemical recurrence after definitive therapy, and 30 patients had CRPC or castor-resistant disease.  These patients had been imaged with a bone scan and a PSMA PET scan within 100 days. And in all patients, the positive predictive value, negative predictive value and specificity for bone scan were evaluated at different time points. They had bone scan and PSMA PET scan and both were compared. And what they found was interesting. All these three values - positive predictive value, negative predictive value, and specificity for bone scan were 0.73, 0.82 and 0.82 in all patients, and in initial staging, it was even lower at 0.43 and 0.94 and 0.80.  So, without getting into too much detail regarding these numbers, I want to highlight the most important part of the study, that at the initial staging, 57% patients who had a positive bone scan had false positive bone scans. The interreader agreement for bone disease was actually moderate for bone scans and quite substantial for the PSMA PET scan.  Dr. Jeanny Aragon-Ching: So, Neeraj, what do you think is the key takeaway message here for our audience?   Dr. Neeraj Agarwal: The key takeaway message is that positive predictive value of bone scan was low in prostate cancer patients at initial staging, with the majority of positive bone scans being false positive. This suggests that a large proportion of patients which we consider to have low-volume metastatic disease by bone scan actually have localized disease. So in the newly diagnosed patients with prostate cancer, patients should ideally have a PSMA PET scan to rule out metastatic disease.   So, let's move on to another abstract I would like to discuss, which has important implications in treatment, especially now that lutetium 177 is approved, but frankly not available widely. Dr. Jeanny Aragon-Ching: Yeah, that's actually very timely. So the abstract you're referring to is 5045, which is being presented by Dr. Yu Yang Sun and colleagues entitled “Effects of Lutetium PSMA 617 on Overall Survival in TheraP Versus VISION Randomized Trials: An Exploratory Analysis.” So, Neeraj, can you tell us more about the relevance of this exploratory analysis? Dr. Neeraj Agarwal: Definitely. In this abstract, Dr. Yang Sun and colleagues assess the effect of lutetium PSMA on overall survival in two different trials, TheraP and VISION trials. So, just for our listeners' recollection, the phase 2 TheraP trial compared lutetium PSMA and cabazitaxel in patients with mCRPC who had progression on docetaxel and had significant PSMA avidity on gallium PSMA pet scan, which was defined as a minimum uptake of SUV max of 20 at least one site of disease and SUV max of more than 10 at all sites of measurable disease.  In this trial, 20 of 101 patients in the cabazitaxel arm crossed over to lutetium PSMA, and 32 of 99 patients in the lutetium PSMA arm crossed over to cabazitaxel. In the VISION trial, patients with mCRPC who previously progressed on at least one ARPI and one taxane-based therapy and had a positive gallium PSMA scan, and here, positivity was not stringently pre-specified as it was done in the context of TheraP trial. So, positive gallium pet scans were randomly assigned in two to one fashion to receive either lutetium PSMA plus best supportive care or standard of care versus standard of care.  And I'd like to highlight that the standard of care comprised ARPIs and bone protecting agents and these patients were not allowed to have cytotoxic chemotherapy such as cabazitaxel in the standard of care arm. Now, overall survival was similar in the lutetium PSMA group regardless of whether they got lutetium PSMA in the VISION trial or TheraP trial. There was no difference in overall survival with lutetium in the lutetium arms of VISION and TheraP trial with a hazard ratio of 0.92. And there was no difference in the overall survival between the lutetium PSMA and the cabazitaxel group in the TheraP trial if you use counterfactual analysis, assuming crossover had not occurred. So, quite interesting in my view. Dr. Jeanny Aragon-Ching: Yeah, thanks Neeraj for that wonderful synopsis and discussion. So, what is the key take home message then? Dr. Neeraj Agarwal: The main message in this new exploratory analysis, which combined both the TheraP and VISION trials, is that lutetium PSMA and cabazitaxel seem to be associated with similar overall survival benefit in these highly selected patients with PSMA positivity. Additionally, the difference in the observed effect of lutetium PSMA and overall survival in the TheraP and VISION trials may be actually better explained by the use of different treatments in the respective control arms of these trials. And these results, in my view, are quite pertinent for those patients and providers who do not have access to lutetium-177 therapy.  Let's go to another abstract that is currently relevant to our practice, given many patients with advanced prostate cancer who have concurrent diabetes; I'm talking about Abstract 5066. Jeanny, can you please tell us more about this abstract?  Dr. Jeanny Aragon-Ching: Certainly, Neeraj. So this abstract will be presented by Dr. Amy Shaver and colleagues. So it's also very relevant, since many men who are diagnosed with prostate cancer frequently also have a concomitant diagnosis of type 2 diabetes mellitus. So, this was a SEER-Medicare population database analysis that looked at men who were treated with either abiraterone or enzalutamide and also had concomitant diagnosis of type 2 diabetes mellitus (DM). And they were identified using ICD-9 and ICD-10 codes and they were all tied in to acute care utilization. So they looked at CMS research data codes and ER hospitalization visits six months after treatment initiation was recorded. So all in all, they took a sample of 11,163 men, of whom close to 62% were treated with abiraterone and about 38% were treated with enzalutamide.  So, of these, about 27% of them had type 2 DM, of whom 59% received abiraterone and about 41% had enzalutamide. So, the bottom line is, compared to those without diabetes mellitus, those who had type 2 diabetes had worse acute care utilization, which was 43% higher than those who got abiraterone compared to enzalutamide, and also had higher overall mortality. Therefore, the bottom line is, having type 2 diabetes mellitus, unfortunately, portends worse outcomes in men with prostate cancer, so careful attention needs to be paid to those who are starting out already with such comorbidities. So Neeraj, any final thoughts you have regarding this abstract and overall before we wrap up on the podcast today?  Dr. Neeraj Agarwal: Absolutely. So it looks like, based on this very important pertinent Abstract 5066, which talks about the impact of diabetes on our patients, I think we need to be very watchful regarding the impact of diabetes on our patients who are being treated with abiraterone or enzalutamide, especially drugs which are known to make the metabolic syndrome and diabetes worse. I think close monitoring and close attention to control of diabetes is very important. So with that, I would urge the listeners to come and join us at the Annual Meeting, not only to celebrate these successes but also to help disseminate this cutting-edge data to practitioners and maximize the benefit to our patients across the globe.   And thank you to our listeners for joining us today. You will find links to the abstracts we discussed today on the transcript of this episode. Finally, if you value the insights that you hear on our ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcast.  Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:  Dr. Neeraj Agarwal @neerajaiims Dr. Jeanny Aragon-Ching Follow ASCO on social media:   @ASCO on Twitter   ASCO on Facebook   ASCO on LinkedIn     Disclosures:  Dr. Neeraj Agarwal:   Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences  Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas  Dr. Jeanny Aragon-Ching: Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant,  Exelixis, Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics.

In Hour one of Live Bet Saturday, hosts Kelley Bydlon and Jonathan Von Tobel are joined by Jonathan Davis, Host of Ice Cap on SiriusXM NHL, as they preview the Weekend Stanley Cup Card. Also on the show, the hosts recap the action from yesterday's NBA Playoff games and preview today's MLB slate.See omnystudio.com/listener for privacy information.

In hour one of A Numbers Game hosts Jonathan Von Tobel and Kelley Bydlon recap last night's NBA Playoffs action and break down the Series prices for the NBA. Also on the show is Jonathan Davis, Host of Ice Cap on SiriusXM NHL, as they discuss what's going on with the Stanley Cup Playoffs.See omnystudio.com/listener for privacy information.

In hour one of A Numbers Game hosts Jonathan Von Tobel and Kelley Bydlon recap last night's NBA Playoffs action and break down the Series prices for the NBA. Also on the show is Jonathan Davis, Host of Ice Cap on SiriusXM NHL, as they discuss what's going on with the Stanley Cup Playoffs.See omnystudio.com/listener for privacy information.

In hour two of A Numbers Game hosts Gill Alexander and Kelley Bydlon are joined by Jonathan Davis, Host of Ice Cap on SiriusXM NHL, Jordan Sherwood, Co-Host of the Unnamed MMA Podcast, and Chris Fallica, Fox Sports, as they share Masters live betting strategies for the weekend, talk some big picture NHL, and break down UFC 287.See omnystudio.com/listener for privacy information.

In hour two of A Numbers Game hosts Gill Alexander and Kelley Bydlon are joined by Jonathan Davis, Host of Ice Cap on SiriusXM NHL, Jordan Sherwood, Co-Host of the Unnamed MMA Podcast, and Chris Fallica, Fox Sports, as they share Masters live betting strategies for the weekend, talk some big picture NHL, and break down UFC 287.See omnystudio.com/listener for privacy information.

In hour one of VSiN Primetime hosts Tim Murray and Shaun King are joined by Red Rock Station Race & Sportsbook Director Chuck Esposito and Jonathan Davis, Host of Ice Cap on SiriusXM NHL, as they give their plays for tonight, discuss today's headlines, and talk NBA and NHL Future Liabilities.See omnystudio.com/listener for privacy information.

Jeff chats with The Athletic's Shayna Goldman about the lack of goaltending between the Panthers and Canadiens, why Matthew Tkachuk has been such a good fit with the Panthers, and why Jonathan Huberdeau's season hasn't gone quite to plan. Host of The Ice Cap on SiriusXM Jonathan Davis talks about the Kings' chances for a deep playoff run, if the Oilers can win with their goaltending tandem, and if Seattle missed the boat on making deadline moves (33:02). George Richards of FloridaHockeyNow.com looks at the offensive bonanza between Florida and Montreal, Anthony Duclair's play since returning from injury, and how All-Star Weekend was received by the locals (49:43). President of the Toronto Six Sami Jo Small discusses her team's upcoming playoff series, the players that we should look out for, and what went into signing Daryl Watts (01:14:30). Producer Matt Marchese wraps things up with his "Week in Review" (01:28:42)! The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the position of Rogers Sports & Media or any affiliates.

In the opening hour of VSiN Primetime, hosts Danny Burke and Adam Burke are joined by Vaughn Dalzell, NBC Sports Betting Analyst, and Jonathan Davis, Host of Ice Cap on SiriusXM NHL, as they break down all the action on the college hardwood and on the ice.See omnystudio.com/listener for privacy information.

In hour two of VSiN Big Bets hosts Dave Ross and Amal Shah are joined by Jonathan Davis, Host of Ice Cap on SiriusXM NHL, as they break down the NHL slate for tonight. Also in the show, the hosts give their thoughts on Russell Westbrook joining the Clippers and how it will effect the 6th Man of the Year market.See omnystudio.com/listener for privacy information.

In hour two of VSiN Big Bets hosts Dave Ross and Amal Shah are joined by Jonathan Davis, Host of Ice Cap on SiriusXM NHL and Host of Show Me The Money Hockey Betting Podcast, as they preview the NHL slate tonight, in addition to sharing their early thoughts on MLB awards, previewing the NBA slate, and discussing the NCAA Tournament O/U Seed.See omnystudio.com/listener for privacy information.

In hour one of VSiN Big Bets hosts Dave Ross and Amal Shah are joined by Jonathan Davis, Host of The Ice Cap on SiriusXM NHL, Host of Show Me The Money Hockey Betting Podcast, as they preview NHL for the night, discuss CBB, and look at Brady and Rodgers Next Team Odds.See omnystudio.com/listener for privacy information.

In hour two of VSiN Big Bets hosts Dave Ross and Amal Shah are joined by Frank Schwab, Covers NFL and Sports Betting for Yahoo Sports, and Jonathan Davis, Host of Ice Cap on SiriusXM NHL, as they talk the NFL and preview action on the ice tonight. Also on the show, the hosts preview the NBA slate and wrap it up with CBB picks.See omnystudio.com/listener for privacy information.

In hour one of VSiN Big Bets hosts Dave Ross and Amal Shah preview the upcoming FIFA World Cup matchups between the United States at Iran, and Wales at England, plus check out the odds on who will be the first pick in the NFL Draft. Also on the show is, Jonathan Davis, Host of Ice Cap on SiriusXM NHL, as they preview tonight's NHL games.See omnystudio.com/listener for privacy information.

Jeff is joined by Jonathan Davis, host of the "Ice Cap" on SiriusXM radio, to talk about the Vegas Golden Knights' early success, why he doesn't believe the Los Angeles Kings have taken the next step forward, and if the Seattle Kraken are as good as their record shows. The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the position of Rogers Sports & Media or any affiliates.